← Back to Search

CAR T-cell Therapy

Digital Health Coaching for Diffuse Large B-Cell Lymphoma

N/A

Waitlist Available

Led By Gretchen McNally, PhD

Research Sponsored by Pack Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up enrollment, months 1,2,3,4,5,6

Awards & highlights

Study Summary

This trial is designed to evaluate quality of life and patient-reported outcomes following CAR T-cell therapy with tisagenlecleucel in adults with diffuse large b-cell lymphoma.

Eligible Conditions

Diffuse Large B-Cell Lymphoma

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ enrollment, months 1,2,3,4,5,6

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~enrollment, months 1,2,3,4,5,6

This trial's timeline: 3 weeks for screening, Varies for treatment, and enrollment, months 1,2,3,4,5,6 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Functional Assessment of Cancer Therapy- Lymphoma (FACT-Lym)

Secondary outcome measures

Cancer Behavior Inventory- Brief (CBI-B)

SF-36

Subjective Assessment of Patient Experience in Managing CAR T Specific Care

Other outcome measures

Digital Engagement

Socio-demographic, clinical, and treatment characteristics

Treatment Response

Trial Design

1Treatment groups

Experimental Treatment

Group I: Single Arm Cohort Receiving Digital Health CoachingExperimental Treatment1 Intervention

A single cohort of up to 100 individuals receiving chimeric antigen receptor T cell therapy will be enrolled in the study, all of whom will be enrolled in a 6-month digital health coaching program. Individuals will be enrolled at The Ohio State University Comprehensive Cancer Center.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

NovartisIndustry Sponsor

1,610 Previous Clinical Trials

2,719,266 Total Patients Enrolled

Ohio State University Comprehensive Cancer CenterOTHER

320 Previous Clinical Trials

290,163 Total Patients Enrolled

Pack HealthLead Sponsor

5 Previous Clinical Trials

1,164 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are currently enrolled in this research?

"Yes, the details found on clinicaltrials.gov suggest that this research is currently seeking volunteers. It was first launched January 25th 2022 and underwent its most recent update April 19th 2022, with a target of 100 patients at one site."

Answered by AI

Are new recruits being accepted for this clinical trial?

"Affirmative. According to clinicaltrials.gov, the trial is actively recruiting for 100 participants at 1 centre and was first posted on January 25th 2022 with a last update occurring April 19th 2022."

Answered by AI

Does this experiment allow for elderly individuals to participate?

"This medical study is searching for participants aged 18 or older, but no more than 90 years old."

Answered by AI

Can I partake in this research endeavor?

"This research project is seeking 100 adults aged between 18 and 90 with b-cell lymphoma, diffuse. Criteria for admission into the study include being of legal age or older, access to a device that can receive calls, text messages, emails and internet connection in order to complete electronic assessments."

Answered by AI

Recent research and studies

Clinical Journal of Oncology NursingJournal

Adult Survivorship: Considerations Following CAR T-cell Therapy

“Adult Survivorship: Considerations Following CAR T-cell Therapy”. 2019. “Adult Survivorship: Considerations Following CAR T-cell Therapy”. Clinical Journal of Oncology Nursing. Oncology Nursing Society (ONS). doi:10.1188/19.cjon.s1.42-48.

Biology of Blood and Marrow TransplantationJournal

Patient-reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities

Chakraborty, Rajshekhar, Surbhi Sidana, Gunjan L. Shah, Michael Scordo, Betty K. Hamilton, and Navneet S. Majhail. 2019. “Patient-reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities”. Biology of Blood and Marrow Transplantation. Elsevier BV. doi:10.1016/j.bbmt.2018.11.025.

Clinical Journal of Oncology NursingJournal

Management Across Settings: An Ambulatory and Community Perspective for Patients Undergoing CAR T-cell Therapy in Multiple Care Settings

“Management Across Settings: An Ambulatory and Community Perspective for Patients Undergoing CAR T-cell Therapy in Multiple Care Settings”. 2019. “Management Across Settings: An Ambulatory and Community Perspective for Patients Undergoing CAR T-cell Therapy in Multiple Care Settings”. Clinical Journal of Oncology Nursing. Oncology Nursing Society (ONS). doi:10.1188/19.cjon.s1.27-34.

European Journal of Oncology NursingJournal